2238 Chapman, Andrew - Thomas Jefferson University - Thomas Jefferson University
Dr. Chapman

Andrew Chapman, DO, FACP

Contact Dr. Chapman

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 923-5676

Most Recent Peer-reviewed Publications

  1. Reply to M.-E. Rougé Bugat et al
  2. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research
  3. Comorbidity in older adults with cancer
  4. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer
  5. Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors
  6. Erratum: Silver oncologic tsunami: Quality issues in the senior adult oncology population (Journal of Oncology Practice (2015) 11, (190-192))
  7. Silver oncologic tsunami: Quality issues in the senior adult oncology population
  8. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer
  9. Randomized phase II trial of irinotecan/docetaxel or irinotecan/docetaxel plus cetuximab for metastatic pancreatic cancer: An eastern cooperative oncology group study
  10. Development of a comprehensive multidisciplinary geriatric oncology center, the Thomas Jefferson university experience
  11. Senior adult oncology: Three cases of advanced cancer in patients of advanced age
  12. Metastatic unknown primary tumor presenting in pregnancy as multiple cerebral infarcts
  13. Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy
  14. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy
  15. Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance
  16. Phase I study of paclitaxel and estramustine: Preliminary activity in hormone-refractory prostate cancer
  17. Multiple drug resistance: Biologic basis and clinical significance in renal-cell carcinoma
  18. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine
0